{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:16:18Z","timestamp":1790680578315,"version":"4.1.0"},"reference-count":18,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,3,1]],"date-time":"2021-03-01T00:00:00Z","timestamp":1614556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,3,1]],"date-time":"2022-03-01T00:00:00Z","timestamp":1646092800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jto.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thoracic Oncology"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1016\/j.jtho.2020.12.007","type":"journal-article","created":{"date-parts":[[2021,2,26]],"date-time":"2021-02-26T00:11:37Z","timestamp":1614298297000},"page":"352-354","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal"],"prefix":"10.1016","volume":"16","author":[{"given":"Arun","family":"Rajan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtho.2020.12.007_bib1","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1111\/imr.12766","article-title":"Immune checkpoint inhibitors: the linchpins of modern immunotherapy","volume":"290","author":"Wilky","year":"2019","journal-title":"Immunol Rev"},{"key":"10.1016\/j.jtho.2020.12.007_bib2","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1200\/JCO.19.00934","article-title":"Five-year overall survival for patients with advanced non-small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study","volume":"37","author":"Garon","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.12.007_bib3","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1200\/JCO.18.00149","article-title":"Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater","volume":"37","author":"Reck","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.12.007_bib4","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41571-019-0218-0","article-title":"Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance","volume":"16","author":"Martins","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.jtho.2020.12.007_bib5","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41568-019-0116-x","article-title":"The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy","volume":"19","author":"Havel","year":"2019","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jtho.2020.12.007_bib6","doi-asserted-by":"crossref","first-page":"54","DOI":"10.21037\/med.2018.08.04","article-title":"Expression patterns and prognostic value of programmed death ligand-1 and programmed death 1 in thymoma and thymic carcinoma","volume":"2","author":"Sekine","year":"2018","journal-title":"Mediastinum"},{"key":"10.1016\/j.jtho.2020.12.007_bib7","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.ccell.2018.01.003","article-title":"The integrated genomic landscape of thymic epithelial tumors","volume":"33","author":"Radovich","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.jtho.2020.12.007_bib8","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s12016-010-8248-5","article-title":"The etiology of paraneoplastic autoimmunity","volume":"42","author":"Maverakis","year":"2012","journal-title":"Clin Rev Allergy Immunol"},{"key":"10.1016\/j.jtho.2020.12.007_bib9","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2015.09.005","article-title":"Thymoma associated with autoimmune diseases: 85 cases and literature review","volume":"15","author":"Bernard","year":"2016","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtho.2020.12.007_bib10","doi-asserted-by":"crossref","first-page":"9056","DOI":"10.3390\/ijms21239056","article-title":"Immunobiology of thymic epithelial tumors: implications for immunotherapy with immune checkpoint inhibitors","volume":"21","author":"Tateo","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jtho.2020.12.007_bib11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.jtho.2020.11.003","article-title":"Durable response in patients with thymic carcinoma treated with pembrolizumab after prolonged follow-up","volume":"16","author":"Giaccone","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.12.007_bib12","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S1470-2045(18)30062-7","article-title":"Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study","volume":"19","author":"Giaccone","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.jtho.2020.12.007_bib13","doi-asserted-by":"crossref","first-page":"1762","DOI":"10.1016\/j.jtho.2018.08.005","article-title":"Systemic therapy in advanced thymic epithelial tumors: insights from the RYTHMIC prospective cohort","volume":"13","author":"Merveilleux du Vignaux","year":"2018","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.jtho.2020.12.007_bib14","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1200\/JCO.2017.77.3184","article-title":"Pembrolizumab for patients with refractory or relapsed thymic epithelial tumor: an open-label phase II trial","volume":"37","author":"Cho","year":"2019","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jtho.2020.12.007_bib15","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1186\/s40425-019-0723-9","article-title":"Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (avelumab) treatment in advanced thymoma","volume":"7","author":"Rajan","year":"2019","journal-title":"J\u00a0Immunother Cancer"},{"key":"10.1016\/j.jtho.2020.12.007_bib16","first-page":"100049","article-title":"Acquired coagulopathy with immune checkpoint inhibitors: an underrecognized association between inflammation and coagulation","volume":"1","author":"Joseph","year":"2020","journal-title":"JTO Clin Res Rep"},{"key":"10.1016\/j.jtho.2020.12.007_bib17","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1136\/annrheumdis-2018-213777","article-title":"Pre-existing antiacetylcholine receptor autoantibodies and B cell lymphopaenia are associated with the development of myositis in patients with thymoma treated with avelumab, an immune checkpoint inhibitor targeting programmed death-ligand 1","volume":"78","author":"Mammen","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.jtho.2020.12.007_bib18","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/ijc.31253","article-title":"WT1 peptide-based immunotherapy for advanced thymic epithelial malignancies","volume":"142","author":"Oji","year":"2018","journal-title":"Int J Cancer"}],"container-title":["Journal of Thoracic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420311163?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1556086420311163?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T10:45:15Z","timestamp":1761561915000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1556086420311163"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3]]},"references-count":18,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["S1556086420311163"],"URL":"https:\/\/doi.org\/10.1016\/j.jtho.2020.12.007","relation":{},"ISSN":["1556-0864"],"issn-type":[{"value":"1556-0864","type":"print"}],"subject":[],"published":{"date-parts":[[2021,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Immunotherapy for Thymic Cancers: A Convoluted Path Toward a Cherished Goal","name":"articletitle","label":"Article Title"},{"value":"Journal of Thoracic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2020.12.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jtho.2020.11.003","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of International Association for the Study of Lung Cancer.","name":"copyright","label":"Copyright"}]}}